Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China.
Department of Science and Education, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China.
Front Immunol. 2024 Oct 23;15:1464635. doi: 10.3389/fimmu.2024.1464635. eCollection 2024.
The predictive accuracy of the preoperative neutrophil-to-lymphocyte ratio (NLR) on the prognosis of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical Bacillus Calmette-Guérin immunotherapy (BCG) after transurethral resection of the bladder tumor (TURBT) remains unknown. Therefore, the current study performed a systematic review and meta-analysis to examine the relationship between preoperative NLR and the prognosis of patients with NMIBC with intravesical BCG immunotherapy.
For this systematic review and meta-analysis, articles were retrieved from PubMed, Cochrane Library, Web of Science, and Embase databases from their inception to 14 May 2024. The role of NLR in predicting recurrence and progression in NMIBC was determined using pooled hazard ratios (HRs) and 95% confidence intervals (CIs).
Seven articles were included in this meta-analysis, involving 4,187 patients. An elevated NLR was significantly associated with recurrence (HR = 2.67, 95% CI = 1.34-5.32, < 0.001) and progression (HR = 1.72, 95% CI = 1.13-2.60, = 0.004) in patients with NMIBC with intravesical BCG immunotherapy.
This meta-analysis demonstrated that elevated preoperative NLR levels were significantly associated with recurrence and disease progression in patients with NMIBC who underwent intravesical BCG immunotherapy after TURBT.
https://inplasy.com/inplasy-2024-7-0058/, identifier 202470058.
经尿道膀胱肿瘤切除术(TURBT)后行膀胱内卡介苗(BCG)免疫治疗的非肌层浸润性膀胱癌(NMIBC)患者,术前中性粒细胞与淋巴细胞比值(NLR)对预后的预测准确性尚不清楚。因此,本研究进行了系统评价和荟萃分析,以检查术前 NLR 与接受膀胱内 BCG 免疫治疗的 NMIBC 患者预后之间的关系。
本系统评价和荟萃分析从 PubMed、Cochrane 图书馆、Web of Science 和 Embase 数据库中检索了从成立到 2024 年 5 月 14 日的文章。使用合并的危险比(HRs)和 95%置信区间(CIs)来确定 NLR 在预测 NMIBC 复发和进展中的作用。
本荟萃分析纳入了 7 项研究,共 4187 名患者。升高的 NLR 与 NMIBC 患者膀胱内 BCG 免疫治疗后复发(HR=2.67,95%CI=1.34-5.32, < 0.001)和进展(HR=1.72,95%CI=1.13-2.60, = 0.004)显著相关。
本荟萃分析表明,术前 NLR 水平升高与接受 TURBT 后行膀胱内 BCG 免疫治疗的 NMIBC 患者的复发和疾病进展显著相关。
https://inplasy.com/inplasy-2024-7-0058/,标识符 202470058。